SPIA
PCRX icon

Steward Partners Investment Advisory’s Pacira BioSciences PCRX Stock Holding History

Steward Partners Investment Advisory’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$920K Buy
36,273
+5,854
+19% +$138K ﹤0.01% 1334
2026
Q1 		$687K Buy
30,419
+10,230
+51% +$227K ﹤0.01% 1355
2025
Q4 		$522K Buy
+20,189
New +$480K ﹤0.01% 1396
2024
Q4 		– Sell
-1,100
Closed -$16.6K – 4062
2024
Q3 		$16.6K Buy
1,100
+200
+22% +$3.42K ﹤0.01% 2737
2024
Q2 		$25.7K Buy
900
+35
+4% +$996 ﹤0.01% 2412
2024
Q1 		$25.3K Hold
865
– – ﹤0.01% 2420
2023
Q4 		$29.2K Sell
865
-150
-15% -$4.39K ﹤0.01% 2213
2023
Q3 		$31.1K Buy
1,015
+185
+22% +$6.67K ﹤0.01% 2119
2023
Q2 		$33.3K Buy
830
+65
+8% +$2.69K ﹤0.01% 2054
2023
Q1 		$31.2K Sell
765
-120
-14% -$4.77K ﹤0.01% 2062
2022
Q4 		$34.2K Sell
885
-50
-5% -$2.43K ﹤0.01% 1985
2022
Q3 		$50K Hold
935
– – ﹤0.01% 1788
2022
Q2 		$55K Hold
935
– – ﹤0.01% 1761
2022
Q1 		$71K Hold
935
– – ﹤0.01% 1750
2021
Q4 		$56K Sell
935
-175
-16% -$9.65K ﹤0.01% 1857
2021
Q3 		$62K Hold
1,110
– – ﹤0.01% 1777
2021
Q2 		$67K Sell
1,110
-210
-16% -$13.3K ﹤0.01% 2789
2021
Q1 		$92.5K Buy
1,320
+75
+6% +$5.36K ﹤0.01% 1669
2020
Q4 		$75K Sell
1,245
-65
-5% -$3.81K ﹤0.01% 1485
2020
Q3 		$79K Buy
1,310
+5
+0.4% +$291 ﹤0.01% 1309
2020
Q2 		$68K Sell
1,305
-99
-7% -$4.14K ﹤0.01% 1291
2020
Q1 		$47K Sell
1,404
-535
-28% -$22.2K ﹤0.01% 1287
2019
Q4 		$87K Sell
1,939
-90
-4% -$3.82K ﹤0.01% 1182
2019
Q3 		$77K Buy
2,029
+379
+23% +$15.1K ﹤0.01% 1190
2019
Q2 		$71K Buy
+1,650
New +$70.1K ﹤0.01% 1199

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steward Partners Investment Advisory's PCRX Position: Q2 2026 in Review

Steward Partners Investment Advisory increased its Pacira BioSciences (PCRX) stake by 19% in Q2 2026, buying an estimated $138K and bringing the position to 36,273 shares worth $920K. The position accounts for ﹤0.01% of the portfolio, ranked #1334.

Steward Partners Investment Advisory first reported a position in PCRX in Q2 2019 and has held it in 25 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Steward Partners Investment Advisory held 36,273 shares of Pacira BioSciences worth $920K as of Q2 2026.
  • Steward Partners Investment Advisory bought 5,854 Pacira BioSciences shares in Q2 2026, an estimated $138K.
  • Pacira BioSciences made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #1334 holding.
  • Steward Partners Investment Advisory first reported a position in Pacira BioSciences in Q2 2019 and has held it in 25 quarters since.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.